Portail Epidemiologie - France

Cette page vous donne accès aux bases de données françaises concernant la Covid-19, recensées sur le Portail. Vous pouvez affiner votre recherche sur ces bases via le moteur de recherche.

Pour consulter d'autres ressources en lien avec la Covid-19, cliquez ici.

Covid-19 : 108 fiches

Tri des résultats :

MDO - Surveillance des maladies à déclaration obligatoire (maladies infectieuses)

Responsable(s) : Coignard Bruno

Version 1

Voir

View

Résumé (apercu rapide)

103

Mise à jour : 14/03/2014

DO-Méso - Déclaration Obligatoire des Mésothéliomes

Responsable(s) : Grange Dorothée
Cherie-Challine Laurence
Buisson Catherine

Version 2

Voir

View

Résumé (apercu rapide)

104

Mise à jour : 22/09/2015

RaDiCo-ECYSCO - European Cystinosis Cohort

Responsable(s) : SERVAIS Aude, Inserm U983
Niaudet Patrick

Version 1

Voir

View

Résumé (apercu rapide)

105

Mise à jour : 03/01/2017

RaDiCo-ECYSCO - European Cystinosis Cohort

Responsable(s) : SERVAIS Aude, Inserm U983
Niaudet Patrick

Objectif principal

The primary objective of the RaDiCo-ECYSCO cohort is to understand the natural history and major long-term manifestations and outcomes of cystinosis in paediatric and adult cases.

Secondary Objectives are to:
• Evaluate the impact of disease and treatments on patients’ quality of life
• Evaluate the effect of treatment on the complications
• appraise the long-term safety of treatment and compliance

Information Technology Objectives are to:
• Develop and diffuse an electronic tool of data collection from various sources linked to a database integrating a system of management and follow-up of data-management allowing collection of data for cystinosis paediatric and adult patients.
• Include data generated by patients and, where relevant, their parents and or carers.
• Expand the cohort to cover a broader European population.
• Promote the use of the RaDiCo-ECYSCO eCRF for mutualisation and harmonisation of data for cystinosis paediatric and adult patients within the expert sites.

Improvement of standard care objectives are to:
• Develop comprehensive evidence based guidelines for treatments as well as for follow-up of patients who will switch from paediatric to adult status,
• Propose a system of audit against the guidelines ensuring overall care is of the highest standard as well as identifying areas of concern for actions.

Critères d'inclusion

The RaDiCo-ECYSCO Cohort inclusion criteria are the following:
• Confirmed diagnosis of cystinosis (based on cystine dosage, presence of crystals at eye examination or molecular diagnosis)
• Signed informed consent

Non-inclusion Criteria
• Patients not able to give their informed consent.
No other non-inclusion criteria (patients with associated disease should be enrolled)

Mise à jour : 03/01/2017

Voir

View

RaDiCo-IDMet - National cohort on imprinting disorders and their metabolic consequences

Responsable(s) : LINGLART Agnes, Inserm U 1169
NETCHINE Irène, INSERM U938, équipe 4

Version 1

Voir

View

Résumé (apercu rapide)

106

Mise à jour : 12/01/2017

RaDiCo-IDMet - National cohort on imprinting disorders and their metabolic consequences

Responsable(s) : LINGLART Agnes, Inserm U 1169
NETCHINE Irène, INSERM U938, équipe 4

Objectif principal

Main objective
The main objective of this study is to describe the natural history of imprinting disorders (IDs) according to their metabolic profile.

Secondary objectives
Secondary objectives are:
• Evaluate the correlation between phenotypes and metabolic profiles at the time of diagnosis.
• Evaluate the risk factor of the various metabolic profiles
• Identify common therapeutic approaches for all IDs (this might lead to the identification of extended applications to all IDs or a larger group of IDs for drugs with so far restricted Marketing Authorization (MA).
• Assess the impact of IDs on quality of life
• Analyse inheritance data of the diseases (search for transmission of (epi)genetic mutations in parents of probands).

Exploratory objectives
• To evaluate the feasibility to use metabolic profiles for clinical classification of IDs
• To develop comprehensive, evidence based guidelines for diagnostic, treatments as well as for follow-up of patients
• To establish a homogenous group of French IDs patients in order to improve knowledge and medical management of IDs.
• To explore the correlation between microbiotia and metabolic profiles in IDs.
• To explore the possibility of using a therapeutic approach already in use for one ID also for other IDs

Information Technology Objectives
• Develop and diffuse an electronic tool of data collection from various sources linked to a database integrating a system of management and follow-up of data-management allowing collection of data for IDs patients.
• Include data generated by patients and, where relevant, their parents and/or carers.

Critères d'inclusion

Inclusion period will last 5 years.
Patients (adults and children) affected with an ID regardless of the severity of the disease,
- with a confirmed diagnosis of ID (based on molecular diagnosis)
- with a signed informed consent for adults or signed informed consent of parents/guardians of minors/ protected adult.

There are no non-inclusion criteria

Mise à jour : 12/01/2017

Voir

View

RaDiCo-PID - Idiopathic Interstitial Pneumonia: From Infancy to Elderly

Responsable(s) : CLEMENT Annick, Inserm UMR S 933

Version 1

Voir

View

Résumé (apercu rapide)

107

Mise à jour : 03/01/2017

RaDiCo-PID - Idiopathic Interstitial Pneumonia: From Infancy to Elderly

Responsable(s) : CLEMENT Annick, Inserm UMR S 933

Objectif principal

Primary Objective
The main objective is to describe the phenotypic features of the paediatric and adult patients with IIP/PID, at diagnosis and during the follow-up. These data will be critical for the description of the natural history of the various forms of IIP/PID.

Secondary Objectives
The secondary objectives are to:
• Identify gene factors involved in disease initiation and progression,
• Investigate the extent to which environmental and co-morbidity factors may influence disease severity and outcome
• Identify and validate biomarkers for disease diagnosis and progression

Exploratory objectives
• Production of improved strategies for patient recruitment and enrolment into clinical trials
• Development of novel strategy for patient follow-up
• Development of novel diagnostic approaches
• Evaluation of effect on natural history of disease, and tolerance of therapy, in a large population in real life
• Development of novel therapeutic approaches

Information Technology Objectives
• Develop and diffuse an electronic tool of data collection from various sources linked to a database integrating a system of management and follow-up of data-management allowing collection of data for IIP/PID paediatric and adult patients.
• Include data generated by patients and, where relevant, their parents and/or carers.

Critères d'inclusion

 Patient with a diagnosis of IIP/PID
IIP/PID diagnosis is established on presenting history, clinical, radiological and functional and if available pathological findings. Inclusion criteria include:
 Clinical criteria: chronic respiratory insufficiency manifestations including dyspnea/tachypnea, cough, and cyanosis during exercise or at rest
 Radiological criteria: characteristic chest High-Resolution Computed Tomography (HRCT) abnormalities including widespread ground glass or alveolar attenuation, reticulation often associated with traction bronchiectasis, and honeycombing
 Functional criteria: pulmonary function test abnormalities reflecting a restrictive pattern and including: loss of lung volume, vital capacity (VC), total lung capacity (TLC); reduction in the diffusion capacity of the lung for carbon monoxide (DLCO), gas exchange abnormalities, and altered ventilatory response to exercise
 Patients (parents/guardians for paediatric/patients) having given an informed consent to participate in the protocol
 Patients affiliated to the “Regime National d’Assurance Maladie”

Non-inclusion Criteria
 Patients with diffuse parenchymal lung diseases caused by drug toxicity, immunodeficiency, proliferative disorders including histiocytosis, and metabolic disorders
 Patients (parents/guardians for paediatric patient) not able to approve/understand the protocol

Mise à jour : 03/01/2017

Voir

View

RaDiCo-ACOEIL - National cohort on congenital defects of the eye: natural history, genetic determinisms and improved ocular and extra-ocular outcome prediction for better patient management

Responsable(s) : Chassaing Nicolas , Inserm U 1056
Calvas Patrick

Version 1

Voir

View

Résumé (apercu rapide)

108

Mise à jour : 03/01/2017

RaDiCo-ACOEIL - National cohort on congenital defects of the eye: natural history, genetic determinisms and improved ocular and extra-ocular outcome prediction for better patient management

Responsable(s) : Chassaing Nicolas , Inserm U 1056
Calvas Patrick

Objectif principal

Main objective
The principal objective of this study is to delineate the long term outcomes of the patients with ocular developmental defects, focusing on visual and neuro-developmental issues.

Secondary objectives
I) Identification of prognostic factors (such as ocular defects, unilateral or bilateral involvement, extra-ocular malformations) that would be associated with unfavourable visual and/or neurologic outcome. These data will be essential for the formulation of recommendations to enhance diagnosis and patient management.
II) Repercussions of the ocular developmental defects on patients and families quality of life.

Exploratory objectives
Searching for potential genotype/phenotype correlations to unravel
- the frequency of implication of each gene in these ocular developmental defects;
- the phenotypic spectrum associated with mutations in these genes;
- the identification of novel genes involved in these ocular developmental defects.
Given genotyping will not be mandatory to participate to the cohort; this objective will involve only the patients who accepted it.

Critères d'inclusion

Patients from 0 to 7 years old
- Newborns and/or children from birth to 7 years old, affected with the following ocular defects:
• anophthalmia,
• microphthalmia
• aniridia
• anterior segment dysgnesis
whose parents will have properly evaluated risks (those related to the actual standard of care for these pathologies) and benefits (improvement of knowledge and standard of care) of the study, and will be given an informed consent to participate the protocol.
- Patients affiliated to the "Régime National d’Assurance Maladie"
- Inclusion of foreign patients will be possible through the French inclusion centers when they agreed to be charged for all medical fees.
Patients over 8 years old
- Children from 8 years old, affected with the following ocular defects :
• anophthalmia,
• microphthalmia
• aniridia
• anterior segment dysgenesis
whose parents will have properly evaluated risks and benefits of the study, and will be given an informed consent form to participate to the protocol.
- Patients affiliated to the "Régime National d’Assurance Maladie"
- Inclusion of foreign patients will be possible through the French inclusion centres when they agreed to be charged for all medical fees.
Adult Patients
- Adults affected with the following ocular defects :
• anophthalmia,
• microphthalmia
• aniridia
• anterior segment dysgenesis
- Adult patients under guardianship whose guardians will have properly evaluated risks (those related to the actual standard of care for these pathologies) and benefits (improvement of knowledge and standard of care) of the study, and will be given an informed consent to participate the protocol. Indeed, intellectual disability may be associated with the ocular defects and we will need to include these patients in order to evaluate incidence of this event.
- Adult patients able to properly evaluate risks (those related to the actual standard of care for these pathologies) and benefits (improvement of knowledge and standard of care) of the study and to give their informed consent to participate to the protocol.
- Adult parents of an affected child participating to the study and willing to participate to the inheritance study (results of DNA analysis).
- Patients affiliated to the "Régime National d’Assurance Maladie".
- Inclusion of foreign patients will be possible through the French inclusion centres when they agreed to be charged for all medical fees.
- Pregnant women can be included in the study (as examination proposed have no interference or adverse effect during pregnancies).

Non-inclusion Criteria
- Patients with ocular developmental defects other than the ones listed above.
- Patient or patients’ parents/tutor not able to approve or declining participation to the protocol.
- French patients not affiliated to the "Régime National d’Assurance Maladie" or foreign patients not willing to pay charges of medical services.

Mise à jour : 03/01/2017

Voir

View

Exporter au format XML

Exporter au format PDF

Exporter au format CSV

MDO - Surveillance des maladies à déclaration obligatoire (maladies infectieuses)

Objectif principal

Critères d'inclusion

DO-Méso - Déclaration Obligatoire des Mésothéliomes

Objectif principal

Critères d'inclusion

RaDiCo-ECYSCO - European Cystinosis Cohort

Objectif principal

Critères d'inclusion

RaDiCo-IDMet - National cohort on imprinting disorders and their metabolic consequences

Objectif principal

Critères d'inclusion

RaDiCo-PID - Idiopathic Interstitial Pneumonia: From Infancy to Elderly

Objectif principal

Critères d'inclusion

RaDiCo-ACOEIL - National cohort on congenital defects of the eye: natural history, genetic determinisms and improved ocular and extra-ocular outcome prediction for better patient management

Objectif principal

Critères d'inclusion

Merci de patienter...

XXX